OR WAIT null SECS
Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.
Avantor announced on April 26, 2021 that it is increasing its global capacity for high-quality single-use technologies used in the production of biologics and vaccines.
According to a company press release, Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe. The expansion will also support customer demand for monoclonal antibodies, cell and gene therapies for oncology and other diseases, and vaccines, including those for COVID-19.
"The industry's response to the COVID-19 pandemic has relied heavily on the integration of single-use products into biopharma production processes,” said Ger Brophy, executive vice-president of Biopharma Production at Avantor, in the press release. “Efficacy and safety are of the utmost importance to our customers, and they look to us to understand and support their requirements as they rapidly expand their own manufacturing capacity. These additions to our global single-use manufacturing ecosystem are critical steps in enabling our customers to get therapies to patients quickly.”